# CJC-1295 Dosage: The Doses Used in the Published Studies

> CJC-1295 dosage in research context: human pharmacokinetic studies used single subcutaneous 30, 60 or 90 µg/kg doses; a mouse study used 2 µg once daily. These are study doses, not human recommendations — each cited.

What doses appeared in the published studies, by what route, in which species — and why the fixed-microgram numbers circulating online are not the same thing.

## What Doses Were Used in the Published Studies

On CJC-1295 dosage, the published studies are specific and few. Human pharmacokinetic work used single subcutaneous doses of 30, 60 or 90 µg/kg: the dose-ranging study administered 30 or 60 µg/kg [1], and the pulsatility study used 60 or 90 µg/kg [3]. In GHRH-knockout mice, the growth study used 2 µg per dose at 24-, 48- or 72-hour intervals, with once-daily dosing fully normalizing growth [4].

These are weight-scaled microgram-per-kilogram doses delivered under study conditions to characterize pharmacokinetics, not regimens for human use. CJC-1295 has no approved human indication, and the studies were designed to measure GH and IGF-1 kinetics — not to establish a safe ongoing dose. Read them as data points, not directions.

## Why the online numbers differ

Community and clinic "protocols" for the no-DAC Modified GRF 1-29 form and for CJC-1295-plus-ipamorelin commonly cite fixed 100–300 µg doses [1]. Those fixed-microgram amounts are not derived from controlled human trials — they are conventions, not findings. The published human doses are the weight-scaled 30–90 µg/kg figures above, used once, to measure kinetics.

The gap matters because the two forms behave completely differently in the body, which is exactly the [DAC vs no-DAC (Modified GRF 1-29)](/dac-vs-no-dac) distinction. A number that makes sense for a short-acting peptide is not interchangeable with one for a multi-day albumin conjugate.

## How much CJC-1295 should I take?

Published human pharmacokinetic studies used single subcutaneous doses of 30, 60 or 90 µg/kg [1][3]. These describe research dosing, not a human recommendation — CJC-1295 has no approved human use, and no study established an ongoing dose for healthy adults. Anyone citing a confident "correct" dose is citing convention, not controlled data.

## How to reconstitute CJC-1295?

In laboratory handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; oral bioavailability is negligible because it is a peptide, so the studied routes are subcutaneous (primary) and intravenous (in early GRF(1-29) pharmacokinetic work) [1]. The four substitutions confer DPP-IV and protease resistance, and DAC conjugation confers the multi-day duration. This describes research handling, not human-use instructions.

## Where to inject CJC-1295?

The route used across the published studies is subcutaneous injection, with intravenous administration used in the early GRF(1-29) pharmacokinetic work [1]. This reflects research methodology; CJC-1295 has no approved human administration, so there is no labeled site or schedule — only the subcutaneous route the studies relied on to measure GH and IGF-1 response.

## Half-life and why it shapes any schedule

The DAC form's estimated half-life of 5.8–8.1 days, with IGF-1 elevation lasting up to 28 days after multiple doses, is why the mouse study could normalize growth with once-daily dosing [1][4]. A multi-day half-life means exposure accumulates very differently from a short-acting peptide — the central reason the [DAC vs no-DAC (Modified GRF 1-29)](/dac-vs-no-dac) difference is not a footnote. The no-DAC form, clearing in minutes to hours, behaves nothing like the conjugate.

## Route and bioavailability

Every dose in the published record was delivered by injection, and that is not incidental. As a peptide, CJC-1295 has negligible oral bioavailability — swallowed, it would be digested before it could act — so the studies used subcutaneous administration as the primary route, with intravenous dosing in the early GRF(1-29) pharmacokinetic work [1]. There is no oral, intranasal, or transdermal form with published human pharmacokinetics.

The four protease-resistant substitutions extend how long the peptide survives in circulation once it is there, but they do not make it survivable in the gut. This is why the entire dose literature is expressed as subcutaneous micrograms-per-kilogram, and why any product promising an oral equivalent is making a claim the published science does not support.

## Why "how much" has no clean answer here

It is worth being blunt about the shape of the evidence. The human doses on record (30–90 µg/kg, single subcutaneous) were chosen to measure pharmacokinetics over days, not to find a safe ongoing regimen, and the long-acting DAC program that would have generated repeat-dose safety data was discontinued [1]. There is no published titration schedule, no established maintenance dose, and no long-term human safety dataset to anchor one.

That absence is the honest answer to most "how much" questions about CJC-1295: the studies tell you what doses produced what hormone response, and they stop there. Anything beyond that — a confident milligram-per-week protocol, a "cycle," an off-label clinical regimen — is extrapolation past the data, on a compound with no approved human use anywhere.

---

A friendly daisy-field notebook on the CJC-1295 research — the GH and IGF-1 numbers walked through gently, the DAC-and-no-DAC difference drawn plainly, and the missing long-term human safety data left honestly blank; nothing here is a clinic, a prescription, or for sale.